Last reviewed · How we verify
"Basel phenotyping cocktail" capsule
A diagnostic cocktail containing probe drugs that assess the activity of multiple cytochrome P450 enzymes and other drug-metabolizing pathways in vivo.
A diagnostic cocktail containing probe drugs that assess the activity of multiple cytochrome P450 enzymes and other drug-metabolizing pathways in vivo. Used for In vivo phenotyping of cytochrome P450 enzyme activity for drug metabolism assessment, Prediction of drug-drug interactions and personalized medicine applications.
At a glance
| Generic name | "Basel phenotyping cocktail" capsule |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Therapeutic area | Pharmacogenomics / Clinical Pharmacology |
| Phase | FDA-approved |
Mechanism of action
The Basel phenotyping cocktail is a research tool used to simultaneously evaluate hepatic metabolic capacity by administering multiple substrate drugs that are metabolized by different CYP450 isoforms (CYP3A4, CYP2D6, CYP2C19, CYP2C9, CYP1A2) and other pathways. Plasma and/or urine concentrations of the probe drugs and their metabolites are measured to phenotype an individual's metabolic status, enabling prediction of drug-drug interactions and personalized dosing.
Approved indications
- In vivo phenotyping of cytochrome P450 enzyme activity for drug metabolism assessment
- Prediction of drug-drug interactions and personalized medicine applications
Common side effects
Key clinical trials
- In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis (NA)
- Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: